^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing
Published date:
08/15/2021
Excerpt:
Two cases of GBM harboring FGFR3-TACC3 fusions were responsive to anlotinib treatment....FGFR1-4 fusions only occur in a minority of cancer cases, and those with glioblastoma harboring FGFR3-TACC3 fusions may benefit from anlotinib.
Source:
Title:
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma
Excerpt:
We describe a case of recurrent glioblastoma treated with anlotinib in this report...The patient was administered anlotinib 12 mg p.o. every day...and oral temozolomide chemotherapy 100 mg/m2...After 2 months of therapy, the patient achieved a partial response that has been maintained for >17 months of follow-up...However, this patient had a favorable clinic outcome, and FGFR3-TACC3 fusion may be a new marker for treatment of glioma with anlotinib. This case study is believed to be the first report that FGFR3-TACC3 fusion could be a novel indication to treat recurrent glioblastoma with the drug anlotinib.
Secondary therapy:
temozolomide
DOI:
10.1002/onco.13530
Trial ID:
